Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.39 |
| ▸ | CA2 | P00918 | 7/20 | 0.39 |
| ▸ | CA9 | Q16790 | 6/20 | 0.39 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CA4 | P22748 | 3/20 | 0.33 |
| ▸ | CA6 | P23280 | 3/20 | 0.33 |
| ▸ | CA5A | P35218 | 3/20 | 0.33 |
| ▸ | CA7 | P43166 | 3/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5327127 | 0.82 | CA2 (0.45) | CA1CA2CA9CA12CA4 | |
| SCHEMBL971368 | 0.82 | L3MBTL1 (0.32) | ALDH1A1SLC9A1SLC9A2L3MBTL1 | |
| SCHEMBL10980384 | 0.80 | L3MBTL1 (0.32) | ALDH1A1SLC9A1SLC9A2L3MBTL1 | |
| SCHEMBL719443 | 0.80 | FABP3 (0.41) | CA1CA2CA9ALDH1A1CA7 | |
| SCHEMBL216708 | 0.80 | TRPV4 (0.38) | ALDH1A1SLC9A1SLC9A2L3MBTL1 | |
| SCHEMBL30010765 | 0.80 | TRPV4 (0.38) | ALDH1A1SLC9A1SLC9A2L3MBTL1 | |
| SCHEMBL9425114 | 0.79 | SLC9A1 (0.31) | SLC9A1SLC9A2 | |
| SCHEMBL3550344 | 0.79 | ACHE (0.47) | ALDH1A1SLC9A1SLC9A2ACHEKDM4E | |
| SCHEMBL11793665 | 0.79 | CA1 (0.33) | CA1CA2CA9CA12CA4 | |
| SCHEMBL10435622 | 0.78 | L3MBTL1 (0.31) | CA1CA2CA9CA7L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313305-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117186109-A | Tetrazine nitrate imitation compound and preparation method thereof | 北京理工大学 | 2023-12-08 | — | — | CN | disclosed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2004080389-A2 | HYDROXYEICOSADIENAMIDE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-09-23 | — | — | WO | disclosed |
| EP-0939629-A4 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO CO (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-0939629-A1 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998003166-A1 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
| EP-0299533-B1 | HIGH POTENCY SWEETENING AGENTS | THE NUTRASWEET COMPANY (a Delaware corporation) (US) | 1993-04-07 | — | — | EP | disclosed |
| WO-1989000563-A1 | HIGH POTENCY SWEETENING AGENTS | THE NUTRASWEET COMPANY (US) | 1989-01-26 | — | — | WO | disclosed |
| EP-0299533-A2 | High potency sweetening agents | THE NUTRASWEET COMPANY (a Delaware corporation) (US) | 1989-01-18 | — | — | EP | disclosed |
| EP-0069585-B1 | COLOR-FORMING SULFONAMIDODIPHENYLAMINES, PHOTOGRAPHIC ELEMENTS CONTAINING THEM AND CORRESPONDING SULFONIMIDE DYES | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-07-03 | — | — | EP | disclosed |
| US-4499304-A | COLOR PHOTOGRAPHY;SILVER HALIDE EMULSIONS; PRINTING PLATES; IMAGES | EASTMAN KODAK COMPANY (US) | 1985-02-12 | — | — | US | disclosed |
| EP-0069585-A1 | Color-forming sulfonamidodiphenylamines, photographic elements containing them and corresponding sulfonimide dyes | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | CA1 4094/4885CA2 1736/4885CA9 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.